bevacizumab,tremelimumab,olaparib,cisplatin,atezolizumab,gemcitabine,sorafenib,pembrolizumab,durvalumab
roche,astrazeneca,pfizer,merck
['imbrave 050', 'key,note,966', 'himalaya', 'gi ', 'oreo']
immunotherapy in #asco23 gi session. incidence of adverse events in #livercancer on himalaya trial related to improved outcome. moreover keynote 966 and imbrave 050 improved quality of life on tx arms. we are not only adding years to life, but life to years!! great start 
Medical oncologist, Hematologists and integrative medicine physician.